DOR BioPharma, Inc. Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC(TM)

MIAMI, FL--(MARKET WIRE)--Jul 6, 2007 -- DOR BioPharma, Inc. (OTC BB:DORB.OB - News) ("DOR" or the "Company") announced today that the European Patent Office has granted a patent, EP 1024827 B1, with claims related to oral vaccination using mutated non-toxic forms of botulinum neurotoxin as a vaccine to prevent exposure to botulinum toxin. The European patent follows the issuance of a patent in the United States, U.S. 6,051,239, which was granted in April, 2000 and contains equivalent claims for oral vaccination. DOR has exclusively licensed these issued patents and related patent applications from Thomas Jefferson University.